Get started
Author

Julia Alcaide

Observed names: Alcaide Julia, Alcaide-Garcia, Julia, Alcaide-García, Julia, J. Alcaide, J. Alcaide Garcia, J. Alcaide García, J. Alcaide-Garcia, Julia Alcaide García, Julia Alcaide-Garcia, Julia Alcaide-García, Julia Alcaide‐Garcia, Julia Alcaide‐García
Observed institutions: Hospital Universitario La Paz, Instituto de Salud Carlos III, Hospital Clínico San Carlos, Hospital Costa del Sol, Hospital Universitario Fundación Alcorcón, Hospital Regional Universitario de Málaga, Osasun Sistemen Ikerketa Institutua, Corporació Sanitària Parc Taulí, Hospital de Galdakao, Hospital Universitario Doctor Peset, Hospital Del Mar, Donostiako Unibertsitate Ospitalea, Andalusian Centre for Nanomedicine and Biotechnology, Agencia Sanitaria Costa del Sol, Hospital Clínico Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Red de Investigación en Servicios de Salud en Enfermedades Crónicas, Universidad de Málaga
ORCID: 0000-0002-9301-1387
Observed ORCID: 0000-0002-9301-1387
OpenAlex ID: A5023894782
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
2024 · T. André, K.-K. Shiu, et al. · Annals of Oncology · 182
PDF
Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience
2014 · Carmen Lopez-Martin, Margarita Garrido Siles, et al. · International Journal of Clinical Pharmacy · 83
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
2018 · E. Aranda, P. García-Alfonso, et al. · European Journal of Cancer · 81
Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
2021 · Thierry Andre, Kai-Keen Shiu, et al. · Journal of Clinical Oncology · 69
The role and prognostic value of apoptosis in colorectal carcinoma
2013 · Julia Alcaide, Rafael Funez, et al. · BMC Clinical Pathology · 43
PDF
Clusterin expression is associated with decreased disease‐free survival of patients with colorectal carcinomas
2010 · Maximino Redondo, Isabel Rodrigo, et al. · Histopathology · 35
PDF
Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in “real world” patients
2017 · A. Godoy-Ortiz, Y. Plata, et al. · Clinical & Translational Oncology · 34
Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer
2022 · M. Benavides, J. Alcaide-Garcia, et al. · ESMO Open · 30
Impact of weight loss on cancer patients’ quality of life at the beginning of the chemotherapy
2020 · Elena Álvaro Sanz, Jimena Abilés, et al. · Supportive Care in Cancer · 29
Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
2022 · Takayuki Yoshino, Thierry Andre, et al. · Cancer Science · 25
PDF
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)
2024 · Carles Pericay, Clara Montagut, et al. · Clinical & Translational Oncology · 23
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
2021 · Diego Salas-Benito, Enrique Conde, et al. · British Journal of Cancer · 23
PDF
Outcomes of open versus laparoscopic surgery in patients with colon cancer
2018 · José M. Quintana, Ane Antón-Ladisla, et al. · European Journal of Surgical Oncology · 23
LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
2023 · K-K. Shiu, T. André, et al. · Annals of Oncology · 22
PDF
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
2022 · Ana Fernández-Montes, Julia Alcaide, et al. · Clinical & Translational Oncology · 22
Gender differences in stage at diagnosis and preoperative radiotherapy in patients with rectal cancer
2020 · Cristina Sarasqueta, Mª Victoria Zunzunegui, et al. · BMC Cancer · 21
PDF
Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])
2014 · P. García Alfonso, M. Benavides, et al. · Annals of Oncology · 21
Influence of depression on survival of colorectal cancer patients drawn from a large prospective cohort
2022 · Esperanza Varela‐Moreno, Francisco Rivas‐Ruiz, et al. · Psycho-Oncology · 20
PDF
El sobrecrecimiento bacteriano de intestino delgado es una entidad frecuente tras gastrectomía, pero con escasa relevancia en el estado nutricional
2018 · Angeles Pérez Aisa, Mari Carmen García Gavilán, et al. · Gastroenterología y Hepatología · 19
Factors Associated with Prolonged Patient-Attributable Delay in the Diagnosis of Colorectal Cancer
2018 · Irene Zarcos-Pedrinaci, Teresa Téllez, et al. · Cancer Research and Treatment · 18
Cost-effectiveness analysis of laparoscopic versus open surgery in colon cancer
2018 · Javier Mar, Ane Anton-Ladislao, et al. · Surgical Endoscopy · 17
511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial
2024 · C. Santos Vivas, J. Vidal Barrull, et al. · Annals of Oncology · 16
PDF
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain
2016 · J. Feliu, I. Díez de Corcuera, et al. · Clinical & Translational Oncology · 16
Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials.
2019 · Manuel Benavides, Eduardo Díaz-Rubio, et al. · PubMed Central · 15
PDF
Impact of Tumor LINE-1 Methylation Level and Neoadjuvant Treatment and Its Association with Colorectal Cancer Survival
2020 · Hatim Boughanem, Gracia María Martin-Nuñez, et al. · Journal of Personalized Medicine · 14
PDF
Works count: 100
Citation count: 1,085
H-index: 19
I10-index: 33
Year
Topic
Type